SCHEMBL23218203

SCHEMBL23218203

CC(C)(C)OC(=O)N1CCN(Cc2cc(Br)cc3c(CO)coc23)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.44
MMP9 P14780 1/20 0.44
MMP13 P45452 1/20 0.44
ADAM17 P78536 1/20 0.44
VEGFA P15692 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
PLA2G7 Q13093 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852890 1.00 MMP1 (0.44) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218353 0.84 MMP1 (0.43) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL19252885 0.79 VEGFA (0.46) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL15191988 0.79 CHRM2 (0.47) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL29852778 0.79 ALDH1A1 (0.40) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218587 0.79 ALDH1A1 (0.40) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL19252873 0.77 CA12 (0.47) MMP1MMP9MMP13ADAM17VEGFA
SCHEMBL23218208 0.77 ALDH1A1 (0.42) MEN1KMT2A
SCHEMBL29592535 0.77 ALDH1A1 (0.42) MEN1KMT2A
SCHEMBL23218220 0.74 DRD2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MMP1 1357/4885MMP9 538/4885MMP13 438/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MMP1 1045/4885MMP9 640/4885MMP13 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.